Successfully reported this slideshow.
Your SlideShare is downloading. ×

April 2019 – Medical Cannabis and Colorectal Cancer Webinar

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad

Check these out next

1 of 51 Ad

April 2019 – Medical Cannabis and Colorectal Cancer Webinar

Download to read offline

There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?

There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?

Advertisement
Advertisement

More Related Content

Slideshows for you (19)

Similar to April 2019 – Medical Cannabis and Colorectal Cancer Webinar (20)

Advertisement

More from Fight Colorectal Cancer (20)

Recently uploaded (20)

Advertisement

April 2019 – Medical Cannabis and Colorectal Cancer Webinar

  1. 1. Clearing the Air: The Role of Medical Marijuana in Cancer Patients
  2. 2. TODAY’S WEBINAR  SPEAKER(S)  Lisa M. Holle, PharmD, BCOP, FHOPA  QUESTIONS  Ask a question in the panel on the RIGHT SIDE of your screen  WEBINAR ARCHIVE  FightCRC.org/webinar  TWEET ALONG  Follow along via Twitter – use the hashtag #CRCWebinar
  3. 3. RESOURCE S TABOO-TY PODCAST MINI MAGAZINES CLINICAL TRIAL FINDER
  4. 4. FIGHTCOLORECTALCANCER DISCLAIMER The information and services provided by Fight Colorectal Cancer are for general informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnoses or treatment. If you are ill, or suspect that you are ill, see a doctor immediately. In an emergency, call 911 or go to the nearest emergency room. Fight Colorectal Cancer never recommends or endorses any specific physicians, products or treatments for any condition.
  5. 5. LisaM.Holle,PharmD,BCOP, FHOPA Bio: Dr. Holle is an Associate Clinical Professor of Pharmacy Practice in the Department of Pharmacy Practice at the UConn School of Medicine. Her current research interests include those which evaluate the impact of oncology pharmacy practice services on patient care, adherence to and patient education/understanding of appropriate use of orally administered oncology medications. Ongoing and future projects will focus on the patient-related outcomes of oncology pharmacy practice care within a team-based approach and pharmacist-led education and cancer risk- assessment/screening in the community pharmacy setting. Past research has included the impact of drug shortages on cancer care; collaborative cancer therapy and supportive care clinical trials in the hematopoietic stem cell and oncology setting; and quality improvement research related to oncology medication safety.
  6. 6. Clearing the Air: The Role of Medical Marijuana in Cancer Patients Lisa M. Holle, PharmD, BCOP, FHOPA Associate Clinical Professor, School of Pharmacy Associate Professor, School of Medicine lisa.holle@uconn.edu
  7. 7. What is Medical Marijuana? • Cannabis – produced from Cannabis sativa/indica/ruderalis – Marijuana – flower/leaves – Hashish – blocks of resin • Cannabinoids – exhibit drug-like effects – Endogenous cannabinoids – Phytocannabinoids – produced by Cannabis sativa and indica species – Synthetic cannabinoids • Medical marijuana – use of phytocannabinoids or synthetic cannabinoids Parmer J, et al. Res Soc Admin Pharm. 2015. [published ahead of print]
  8. 8. Medical Marijuana History Western Medicine Marihuana Tax Act Narcotic Schedule I Compass- ionate Use Synthetic drugs Medical Use CBD Oral Solution FDA approved CBD, cannabidiol. National Cancer Institute. Available at: http://www.cancer.gov/about- cancer/treatment/cam/hp/cannabis-pdq#section/_5 . Accessed March 24, 2019. 1840s 1937 1951 1970 1971-1990 1986 1980s-90s 2018
  9. 9. Medical Marijuana. ProCon.org. Available at: https://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Accessed March 24, 2019.
  10. 10. Differences in State Medical Marijuana Programs • Laws very greatly • Approved conditions • Possession amounts/cultivation allowed • Registration processes • Allow dispensaries (does not allow dispensaries OR, NE, MI, HI) • Pharmacist oversight of dispensaries (AK, CT, MN, NY, OK, PA); marijuana pharmacies (LA, UT) • Specify conditions in which it can be used • Recognize patients from other status (AZ, AR, ME, MI, NE, NH, OK, RI) Medical Marijuana. ProConorg. Available at: https://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Accessed 5 Jan 2019.
  11. 11. How Medical Marijuana Works In the Body
  12. 12. What Are The Different Types Recreated from Turgeman I, et al. Expert Opin Invest Drugs. 2018 (in press): DOI: 10.1080/13543784.2019.1561859. Cannabis Plant (sativa, indica, ruderalis) Phytocannabinoid THC CBD Cannabinol Tetrahydro- cannabivarin Cannabigerol Terpenoid Limonen Terinolen Pinene Flavonoid Canna- flavin A Orientin Quercetin • Anandamide • 2-arachidononyl- gylcerol Endogenous Cannabinoid System • Classical •Nabilone •Dronabinol • Nonclassical •JWH-018 •Methanadmide •AM4030 Synthetic Cannabinoids
  13. 13. What Effects Does it Have? Recreated from Turgeman I, et al. Expert Opin Invest Drugs. 2018 (in press): DOI: 10.1080/13543784.2019.1561859. • Cannabinoids in marijuana – Delta-9- tetrahydrocannabidiol (THC) – Cannabidiol (CBD)
  14. 14. Biologic Effects Guzman M. N Rev Cancer. 2003;3:745-755. CB1 – central and peripheral neurons; CB2 – immune system.
  15. 15. How You Can Take Medical Marijuana Bowels DW, et al. Crit Rev Oncol/Hematol. 2012;83:1-10; Kramer JL. CA Cancer J Clin. 2015;65:109-122. • Inhalation • Oral • Rectal • Sublingual • Transdermal • Ophthalmic • Intrathecal • Intravenous
  16. 16. What About CBD Oil? • 2014 United States Farm Act – Classified industrial hemp as containing < 0.3% THC – Allowed to be sold in all 50 states – Other ingredients? – Regulated?
  17. 17. FDA Approved Synthetic Products • Dronabinol (Marinol®) – Synthetic THC – CINV failing other treatments – Weight loss and anorexia with AIDS – Schedule III • Nabilone (Cesamet®) – Synthetic THC-mimetic – CINV failing other treatments – Schedule II CINV, chemotherapy-induced nausea and vomiting; FDA, US Food and Drug Administration. Bowels DW, et al. Crit Rev Oncol/Hematol. 2012;83:1-10; Kramer JL. CA Cancer J Clin. 2015;65:109-122.
  18. 18. Approved Oral Products Nabiximols (Sativex®) • THC + CBD extract • Multiple sclerosis and cancer pain • Not available in US Cannabidiol (Epidiolex®) • Plant-derived oral CBD solution • June 2018: FDA approved • Treatment of seizures associated with Lenox- Gastaut syndrome or Dravet syndrome in patients > 2 years • September 2018 – DEA Schedule 5 • CT: Schedule 2 FDA, US Food and Drug Administration Approved. Drug Enforcement Agency. Available at: https://www.dea.gov/press-releases/2018/09/27/fda-approved-drug- epidiolex-placed-schedule-v-controlled-substance-act. Accessed March 24, 2019.
  19. 19. How Your Body Absorbs It Dosage Form Absorption Peak Level Factors Impacting Absorption Bioavailability Inhalation Quick fast, rapid delivery to brain 22 min Depth of inhalation, frequency of puffs, breath hold Varies: 2-56% Heavy: 23-27% Occasional: 10-14% Oral Slow 1-2 h; up to 8 h Degradation of drug in stomach and first-pass 10-20% Oral-mucosal/ buccal Fast 30 min High first-pass metabolism 10-20% Rectal Fast 15 min Low first-pass metabolism 20-40% Transcutaneous Slow 2 hr; up to 48 h Transport across skin layers; no first-pass metabolism 10% Oberbarnscheidt T, et al. J Addict Res Ther. 2017;S11:012. Crosses placenta and into breast milk.
  20. 20. How Your Body Digests It • Metabolism – Liver metabolism – Other metabolism: brain, intestine, lung • Drug Interactions – Medications that cause drowsiness/dizziness – Many potential interactions CBD, cannabidiol; CYP450, cytochrome P450; THC, delta-9-tetrahydrocannabinoid. MacCallum CA, et al. Eur J Inter Med. 2018;49:12-19; Epidiolex [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc: 2018.
  21. 21. What’s the Evidence?
  22. 22. Cancer Treatment • Multiple pathways explored in preclinical models • Phase I refractory glioblastoma • Case report: astrocytomas • Case report: acute lymphoblastic leukemia • In progress – Phase II placebo-controlled THC:CBD preparation + temozolomide in glioblastoma – safe; survival advantage – Phase II nabiximols + temozolomide in glioblastoma – Two phase I dexananibol – advanced solid tumors and brain cancers – Retrospective review of immunotherapy + cannabis effects CBD, cannabidiol; THC, delta-9-tetrahydrocannabinoid. Turgeman I, et al. Expert Opin Invest Drugs. 2018 (in press): DOI: 10.1080/13543784.2019.156185.
  23. 23. Immunotherapy and Cannabis • Retrospective review of nivolumab-treated patients at Ramban Health Care Campus; Haifa, Israel • N=140 patients (nivolumab, 89; nivolumab + cannabis, 51) • Advanced melanoma, non-small cell lung cancer, renal cell carcinoma • Results – Cannabis only factor which reduced reduced response rate (nivolumab, 37%; combination, 15.9% – Cannabis did not affect overall or progression-free survival Taha T, et al. Ann Oncol. 2017;28(5):1545PD.
  24. 24. Cancer Symptoms
  25. 25. Nausea and Vomiting • 30 studies published – Smoked THC – Synthetic cannabinoids – Nabiximols • Meta-analysis found compared with placebo – Significantly more effective for nausea and vomiting • Not evaluated with current antiemetic regimens
  26. 26. Cancer-Associated Pain Study Design Patients Therapy Results Noyes 1975 RCT/DB/PC Cancer pain N=10 Dronabinol 5mg, 10mg 15mg and 20mg vs placebo 15 and 20 mg - substantial analgesic effects; antiemesis and appetite stimulation; 20 mg = 120 mg codeine Johnson 2010 RCT/DB/PC Cancer pain N=177 Nabiximols vs THC 2.7 mg oromucosal spray vs placebo • Significantly improved mean pain score; > 30% reduction in pain from baseline score for THC/CBD product • No change for THC product • No change in mean opioid dose or breakthrough doses Portenoy 2012 RCT/DB/PC Cancer pain N=360 Nabiximols (low, medium, high dose) vs placebo • Better pain control and sleep disruption with low dose compared with placebo • Adverse events dose related Lynch 2014 RCT/PC CIN N=16 Nabiximols vs placebo • No statistical difference on numeric pain rating • 5 responders decreased 2.6 on 11-pt scale CBD, cannabidiol; DB, double-blind; PC, placebo-controlled; RCT, randomized controlled trial; THC, delta-9-tetrahydrocannabinoid. Noyes R, et al. Clin Pharmacol Therp. 1975;18;84-89; Noyes R, et al. J Clin Pharmacol. 1975;15:139-143; Johnson JR, et al. J Symptom Manage. 2010;39:167-178; Portenoy RK, et al. J Pain. 2012;13:438-449; Lynch ME, et al. J Symptom Manage. 2014;47:166- 173.
  27. 27. Anorexia/Weight Gain • Appetite increase: 49% • Weight gain: 3%Dronabinol 2.5 mg po BID + placebo • Appetite increase: 75% (P=.0001) • Weight gain: 11% (P=.02) • Improved QOL and toxicity Megestrol 800 mg po daily + placebo • Appetite increase: 66% (P=.17) • Weight gain: 8% (P=.43) Dronabinol 2.5 mg BID + Megestrol 800 mg po daily Randomized, double-blind, parallel group N=469 Advanced cancer Weight loss QOL, quality of life. Jatoi A, et al. J Clin Oncol. 2002;20:567-573; Strasser F, et al . J Clin Oncol. 2006;24:3394-3400.
  28. 28. Anorexia & Cachexia Increased appetite: • Cannabis extract: 73% • THC: 58% • Placebo: 69% No significant differences in: • Appetite • QOL • Toxicity Cannabis extract (THC 2.5 mg CBD: 1 mg) (n=66) THC 2.5 mg (n=65) Adult patients Advanced cancer Cancer-related anorexia and/or cachexia ECOG PS < 2 R A N D O M I Z E D 2:2:1 ECOG, Eastern Cooperative Oncology Group; CBD, cannabidiol; THC, delta-9- tetrahydrocannabinoid. Strasser F, et al. J Clin Oncol. 2006;24:3394-3400. Placebo (n=33)
  29. 29. Cannabinoids for Insomnia • Meta-analysis of 19 placebo-controlled studies – Cannabis-products evaluated for other indications and evaluated sleep – Nabiximols: 13 studies – THC/CBD capsules: 2 studies – Smoked THC: 2 studies – Dronabinol: 1 study – Nabilone: 1 study • Greater average improvement in – Sleep quality – Sleep disturbance CBD, cannabidiol; CI, confidence interval; THC, delta-9-tetrahydrocannabinoid. Whiting PF, et al. JAMA. 2015;313:2456-2473.
  30. 30. Depression and Anxiety • No studies specific in cancer patients • Meta-analyses of indications – No well designed trials evaluating depression – Depression as an outcome: no difference found compared with placebo – Positive for individuals with social anxiety and anxiety in chronic pain patients Whiting PF, et al. JAMA. 2015;313:2456-2473.
  31. 31. Adverse Effects of Cannabis-Based Medications Most Common Common Rare Drowsiness/fatigue Euphoria Orthostatic hypotension Dizziness Blurred vision Toxic psychosis/paranoia Dry mouth Headache Depression Cough/phlegm/ bronchitis (smoking only) Ataxia/dyscoordination Anxiety Tachycardia (after titration) Nausea Hyperemesis Cognitive effects Diarrhea MacCallum CA, et al. Eur J Inter Med. 2018;49:12-19. • Schizophrenia/bipolar disorder, long-term cognitive dysfunction
  32. 32. COMPASS Study •Nonserious AEs: 88.4% vs 85.2% •Cannabis: nervous system, GI, respiratory •Serious adverse effects: 13% (cannabis) vs 19% •Deaths: 0% vs 1% Primary objective Assess risk of adverse events •No significant change in pulmonary function tests •No difference in neurocognition at 1 year •No changes in liver, renal, or endocrine labs •Significant reduction in average pain intensity at 1 yr: change, 0.92 vs 0.18 •QOL; 2.36 points greater with cannabis Secondary objective Pulmonary function Neurocognitive function Other safety Effect on pain and QOL AE; adverse events; QOL, quality of life; THC; delta-9-tetrahydrocannabinoid. Ware MA, et al. J Pain. 2015;16:1233-1241. Prospective, cohort study Jan 2004-April 2008 Adults chronic non-cancer pain using cannabis (12.5% THC), any delivery system vs control population
  33. 33. Cannabinoid Hyperemesis Syndrome • Recurrent paroxysmal episodes of nausea/vomiting in chronic users • Mitigated by frequent hot bathing/showering • Complications: acute renal failure, electrolyte depletion, pnuemomediastinum • Acute treatment – Replace fluids – Medications • Antiemetic • Anxiolytics • Antiphsycotics • Capsaicin topical – Hot showers • Long-term treatment – Stop cannabis use N/V nausea and vomiting; 5HT3; 5-hydroxytryptamin or serotonin. Richards JR, et al. Pharmacother. 2017;37:725-734; Health Canada. https://www.canada.ca/content/dam/hc-sc/documents/services/drugs- medication/cannabis/information-medical-practitioners/information-health-care-professionals- cannabis-cannabinoids-eng.pdf. Accessed March 24, 2019.
  34. 34. Contraindications • Allergy to any cannabinoid • Past history of psychotic disorder • Active or unstable cardiovascular disease Caution • Pregnant or nursing women • Potential for dependence/abuse • Driving Canadian Consortium for the Investigation of Cannabinoids. Available at www.ccic.net. Accessed March 24, 2019.
  35. 35. Now That You Have the Evidence….
  36. 36. What are Legal Implications? State laws allow US Dept Justice stance Patient benefits Schedule I Institution stance Medical association stance Hill. JAMA. 2015;313:2474-2480.
  37. 37. When to Use? • Qualifying condition • Multiple failed trials of first- and second-line pharmacotherapies • Failed trial of FDA approved cannabinoid • No active substance, psychiatric, unstable mood or anxiety disorder Hill. JAMA. 2015;313:2474-2480.
  38. 38. State Medical Marijuana Programs • Provider certifies patient with qualifying condition • Patient registers, some states allow caregivers • Go to dispensary to purchase product Department of Consumer Protection Medical Marijuana Program. Available at: https://portal.ct.gov/DCP/Medical-Marijuana-Program/Medical-Marijuana- Statistics. Accessed March 24, 2019.
  39. 39. CT Qualifying Conditions - Adults Amyotrophic lateral sclerosis HIV/AIDS Post herpetic neuralgia Cachexia Intractable HA syndrome Psoriasis (severe) Cancer Multiple sclerosis Psoriatic arthritis Cerebral palsy Muscular dystrophy Rheumatoid arthritis severe Complex regional pain syndrome Hydrocephalus with intractable HA Terminal illness requiring end- of-life care Crohn’s disease Neuropathic facial pain Sickle cell disease Cystic fibrosis Osteogenesis imperfecta Ulcerative colitis Epilepsy Parkinson disease Uncontrolled intractable seizure disorder Glaucoma PTSD Wasting syndrome Damage to spinal cord with intractable spasticity or irreversible cord injury Fibromyalgia (spasticity/neuropathic pain) Post laminectomy syndrome with chronic radiculopathy Department of Consumer Protection Medical Marijuana Program. Available at: https://portal.ct.gov/DCP/Medical-Marijuana-Program/Qualification- Requirements. Accessed March 24, 2019.
  40. 40. CT Qualifying Conditions - Children Cerebral palsy Cystic fibrosis Irreversible spinal cord injury with objective neurological indication of intractable spasticity Muscular dystrophy Osteogenesis imperfecta Severe epilepsy Terminal illness requiring end-of-life care Uncontrolled intractable seizure disorder Department of Consumer Protection Medical Marijuana Program. Available at: https://portal.ct.gov/DCP/Medical-Marijuana-Program/Qualification- Requirements. Accessed March 24, 2019
  41. 41. Dispensaries in CT • CT licensed pharmacists • Similar restrictions/requirements as pharmacy • Security system • Qualified patients and caregivers allowed in facility • No compounding • Review PMP Department of Consumer Protection Medical Marijuana Program. Available at: https://portal.ct.gov/DCP/Medical-Marijuana-Program/Dispensary-Facility. Accessed March 24, 2019.
  42. 42. Dispensary Pharmacist’s Role • Complete an initial patient assessment – What symptoms require relief? – Naïve vs experienced user – Patient’s lifestyle • Help patient select product – Strain, dosage form, delivery device – Variations on time to effect, adverse effects • Equip patient with tools to self- assess efficacy of product • Report any adverse events that may occur
  43. 43. Medical Marijuana in Hospitals • Pharmacologic implications • Legal challenges • Federal compliance for funding/licensure • Acquisition of product • Other considerations – No smoking policy – Training – Monitoring/outcomes • Typical policies – Not allowed for inpatients
  44. 44. How Your Healthcare Provider Should Monitor Your Use • Changes in – Medical condition/symptoms – Physical or psychosocial function – Medication list • Efficacy of treatment • Adverse effects • Liver function tests? • Safety of use (possible diversion, driving/equipment use) • Goals of treatment • Progress towards goals Medical Board of California. Available at: https://www.mbc.ca.gov/Publications/guidelines_cannabis_recommendation.pdf. Accessed 6 January 2019; Epidiolex [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc: 2018..
  45. 45. What You Need To Know • Registration process • Variability of quality and concentration of cannabis • Dosing and dosage forms (start low and go slow) • Potential risks of cannabis – Adverse effects – Pregnancy/lactation – Drug interactions • Financing, travel • Safeguards to prevent diversion • Symptom inventory chart Medical Board of California. Available at: https://www.mbc.ca.gov/Publications/guidelines_cannabis_recommendation.pdf. Accessed 6 January 2019.
  46. 46. Summary • THC and CBD are primarily responsible for medicinal effects • Limited data supports medical marijuana use in cancer and associated symptoms; yet many patients have benefit. This may be due to the lack of well designed studies • Most side effects are transient and can be treated by adjusting doses • Patient certification process can be facilitated by dispensary staff
  47. 47. Resources • Centers for Disease Control: https://www.cdc.gov/marijuana/index.htm • NIH: https://nccih.nih.gov/health/marijuana • Health Canada: https://www.canada.ca/en/health- canada/topics/cannabis-for-medical- purposes.html
  48. 48. Questions?
  49. 49. Q & A SNAP A #STRONGARMSELFIE In 2018, up to $55,000 will be donated thanks to our sponsors: Bayer, Fujifilm, Myriad Genetics and Taiho Oncology! Flex a “strong arm” & post it to Twitter or Instagram using the hashtag #StrongArmSelfie
  50. 50. CONTACT US CALL TOLL FREE 1.877.427.2111

Editor's Notes

  • pain
  • PERMISSION: Need to request – found on this site: http://marijuanaindustrygroup.org/

×